28 results about "Cleavable linker" patented technology

The efficacy and indication of donanemab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.

The present disclosure provides methods of polynucleotide synthesis and compounds, compositions useful for synthesis of polynucleotides. The chemical compounds include nucleotides and their analogs that are attached to polymerase though a cleavable linker comprising an enzymatically cleavable amino acid ester.

Compositions and methods are provided of a therapeutic nanoparticle composed of collagenase IV linked via a linker (e.g. cathepsin B cleavable linker) to ferumoxytol (iron oxide). The collagenase IV is key in the composition intended for the breakdown of the tumor wall as the collagenase. Such compositions and methods are aimed at solving at the same time two of the main challenges of current approaches in the treatment of glioblastoma multiforme (GBM) which are low specificity and poor uptake.

The invention is directed to self-eliminating cleavable conjugates according to general formula (I) or (II) wherein AR is capable of an elimination reaction upon cleavage of CL.

The present disclosure relates to multifunctional molecules comprising masked interleukin 12 and methods of making and using the same. In certain embodiments, the multifunctional molecules disclosed herein comprise a cleavable linker.

To provide a method for purifying peptides or peptide nucleic acids produced by solid-phase peptide synthesis in a way that is inexpensive and is less prone to faults, and linker molecules for use in the purification.SOLUTION: The present invention relates to linker molecules of formula (1), X-Tb-Va-U-Y-Z (1) and a method for purifying peptides using the linker molecules. The linker molecule can be coupled to a purification resin via the moiety X and to a peptide via the moiety Y under the release of the leaving group Z. T is an optional spacer moiety and V is an optional electron withdrawing moiety. U is an aryl or 5- or 6-membered heteroaryl moiety bound to at least one electron withdrawing moiety V, W, or E. The linker is stable under acidic conditions and releases the peptide upon addition of a reducing agent.SELECTED DRAWING: None

This invention relates to a branched, enzyme-cleavable linker-payload and a method for its efficient production.

Disclosed herein, inter alia, are silicon containing cleavable linkers and compounds for use in nucleic acid sequencing.

The present disclosure provides tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutics to a tumor cell environment. The present disclosure also provides cleavage products of said drugs and prodrugs, and methods related to the use of the same.

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a —S(═O)(═N—)— functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and / or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

The present disclosure relates generally to cleavable linkers and uses thereof.SOLUTION: A multi-targeted molecule comprising at least two effector molecules, wherein said effector molecules are linked together via an endosomal cleavable linker or a protease cleavable linker, wherein said linker is a carbohydrate linker, and wherein said linker is cleaved at least 1.25 times faster in cells (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).SELECTED DRAWING: None

The specification relates to conjugates of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.

The efficacy and indication of belimumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors

The present disclosure provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan and a pro-payload molecule comprising a payload scaffolding molecule operably and reversibly linked to a payload molecule through a cleavable linker. The disclosure further provides methods of making and methods of using the particulate delivery system.

Provided herein are dye-drug conjugate (DDC) compounds comprising: a tumor-targeting near-infrared dye; a chemotherapeutic drug; and a cleavable linker, and methods of use thereof.

The present specification relates to conjugates comprising a linker of formula (IA) and pharmaceutically acceptable salts thereof. The specification also relates to the use of these conjugates for the treatment of diseases, such as cancer, and intermediates useful in the synthesis of these conjugates. IA

This disclosure relates to a multifunctional molecule containing a shielding interleukin 12, and to methods for fabricating and using the same. In certain embodiments, the multifunctional molecule disclosed herein includes a cleavable linker.

The present specification relates to conjugates comprising a linker of formula (IA): and pharmaceutically acceptable salts thereof. The specification also relates to the use of these conjugates for the treatment of diseases such as cancer, as well as intermediates useful in the synthesis of these conjugates.

The efficacy and indication of Aducanumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors

Compositions and methods of use are provided that among other things, allow for efficient adapter ligation to small RNAs. Embodiments of the compositions include partially double stranded polynucleotides for use as 3′ adapters that contain a cleavable linker positioned between a single-stranded region and a double-stranded region. Upon ligating the 3′ adapters, the single-stranded region is released by cleaving the cleavable linker.

A modified dye and use thereof. Specifically, provided is a class of compounds with novel structures or stereoisomers or salts thereof. The compound is structurally designed on the basis of a disulfide bond, and can be used as a cleavable linker to be linked to a fluorescent dye. The fluorescent dye linked to the aforementioned compound or isomer or salt thereof is cut off by means of the cleavable linker after photographing is completed, and then sequencing in the next cycle is performed. Compared with existing linkers, when the fluorescent dye linked to the aforementioned compound or isomer or salt thereof is used for sequencing (such as COOLMPS sequencing), the background signal can be significantly reduced.

Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

Provided herein are dye-drug conjugate (DDC) compounds comprising: a tumor-targeting near- infrared dye; a chemotherapeutic drug: and a cleavable linker, and methods of use thereof.

The present specification relates to conjugates comprising a linker of formula (IMA): (IMA) and pharmaceutically acceptable salts thereof. The specification also relates to the use of these conjugates for the treatment of diseases, such as cancer, and intermediates useful in the synthesis of these conjugates.